PMID: 16520663Mar 8, 2006Paper

Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer

Anti-cancer Drugs
Thierry PetitEsteban Cvitkovic

Abstract

A phase II study was conducted to evaluate the safety and efficacy of an oxaliplatin (OXA)/vinorelbine (VNB) combination in metastatic breast cancer (MBC) patients pre-treated with anthracyclines and taxanes. Patients received OXA at 130 mg/m (2-h i.v.), day 1, and VNB days 1 and 8 at 24-26 mg/m repeated every 3 weeks. Forty-two patients (median age 54; 64% with liver metastasis, 67% taxane resistant/refractory and 38% anthracycline resistant/refractory) were treated. A median of 4 cycles of treatment was given per patient, with 31% receiving 6 or more. Eleven partial responses and 16 patients with stable disease (five lasting more than 4 months) in 41 eligible patients were seen, for an overall response rate of 26.8% (95% confidence interval 14.2-42.9). Median follow-up was 15.9 months (7.2-30.6), median time to progression was 3.4 months and estimated overall survival was 12.7 months (20 events). Thirty-three patients experienced (National Cancer Institute Common Toxicity Criteria version 2) grade 3-4 neutropenia (one case of febrile neutropenia) and three patients had severe constipation requiring hospitalization. Nine patients developed grade 3 OXA-specific neurotoxicity. There were no treatment-related deaths. We conclude ...Continue Reading

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Oct 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S JonesJ Hohneker
Nov 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B L WeberJ Hohneker
Jan 1, 1996·Clinical Pharmacology and Therapeutics·I RobieuxS Monfardini
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M J PiccartE Cvitkovic
Dec 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V DierasM Marty
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R B LivingstonC A Long
Dec 3, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E RaymondE Cvitkovic
Feb 22, 2000·British Journal of Cancer·X PivotG Hortobagyi
Mar 31, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D I UdomR C Coombes
Oct 3, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A BerrutiL Dogliotti
Oct 20, 2000·Molecular Pharmacology·J M WoynarowskiP E Juniewicz
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G V KornekW Scheithauer
Apr 13, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C GarufiE Terzoli
Feb 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I MonnetE Cvitkovic
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L ZelekM Spielmann
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W SledgeWilliam C Wood
Jul 26, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P ReichardtH J Lück
Feb 14, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P FumoleauM Namer
Dec 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo CristofanilliGabriel N Hortobagyi
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy D MillerHope S Rugo

❮ Previous
Next ❯

Citations

Aug 21, 2013·Progress in Neurobiology·C Patte-MensahA G Mensah-Nyagan
May 3, 2008·Seminars in Oncology·Windy Dean-Colomb, Francisco J Esteva
Oct 22, 2008·Expert Opinion on Pharmacotherapy·Jacques Bonneterre, Nicolas Penel
Sep 23, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Changmin KimSun Kwang Kim
Jan 18, 2012·Chemotherapy·Ali I Shamseddine, Fadi S Farhat
Nov 26, 2008·Journal of Chemotherapy·F MeriggiA Zaniboni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.